Topotecan Weekly Versus Topotecan Day 1-5 in Patient With Platin-resistant Ovarian Cancer

Topotecan Weekly Versus Topotecan Day 1-5 in Patient With Platin-resistant Ovarian Cancer

Comparison of topotecan weekly vs. topotecan day 1-5. The compatibility and activity are to be examined.

Topotecan belongs to the most effective medicaments in the therapy of relapsed platin-resistant ovarian cancer. Due to the low rate of hematological toxicities of grade 3 or 4 weekly application may be an improvement of therapy. None randomised study exists comparing a weekly topotecan application with an application on day 1-5. This study will compare the two applications in regard to: rate of complete or partial remissions, rate of toxicity, quality of life, progression free survival, overall survival.

Inclusion Criteria:

• patients with histologically-confirmed ovarian cancer
• relapse within 6 month after primary therapy
• primary therapy with platin and taxan
• ECOG 0-2
• >= 18 years
• leukocytes >= 3.000/ µl
• platelet >= 100.000/ µl
• neutrophil >= 1.500/ µl
• written informed consent

Exclusion Criteria:

• earlier topotecan therapy
• simultaneous or planned radiotherapy
• secondary malignancy